Journal of Isfahan Medical School

Journal of Isfahan Medical School

The Effect of N-Acetylcysteine in Prime Solution on Preventing Renal Failure during Cardiopulmonary Bypass Surgery

Document Type : Original Article (s)

Authors
Leila Roustazadeh 1
Mehran Shahzamni 2
Alireza Hoseini
Raheleh Routazadeh 3
1 MSc in Circulatory Technology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Assistant Professor, Department of Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 PhD Student, School of Chemical Engineering, Isfahan University of Technology, Isfahan, Iran
10.22122/jims.v39i624.13812
Abstract
Background: Cardiopulmonary bypass (CPB) has many benefits in improving heart surgery; but this method may cause kidney damage and kidney failure in some patients. N-acetylcysteine (NAC) is an anti-inflammatory agent that has protective effects on kidney function. The aim of the present study was to evaluate the effects of NAC on prevention of renal failure following CPB.Methods: In this double-blind clinical trial study, 100 patients who were candidates for coronary artery bypass grafting (CABG) at Shahid Chamran hospital in Isfahan, Iran, aged 40-65 years with glomerular filtration rate (GFR) of greater than 60 and creatinine level of less than 1.5 mg/dl were selected. The intervention group received 1200 mg of NAC in Prime solution. NAC was not used in the control group. The two groups were compared in terms of GFR and mortality. Data on blood levels of urea, creatinine, urine output, and intensive care unit (ICU) stay were collected.Findings: Patients in the two groups had relatively similar conditions in terms of mean age, height, weight, aortic clamp time, and pump. No mortality was reported in any of the groups. There was no significant difference between the ICU stay and the amount of urea in the two groups of intervention and control (P > 0.050). There was a significant difference in the urine output of patients in both groups in the first 24 hours after CPB (P < 0.050); but in the second 24 hours, the difference was not significant. There was significant differences in creatinine and GFR levels of patients with diabetes mellitus in the intervention group with other patients (P < 0.050). No patient death was reported in any of the statistical population groups.Conclusion: The results show that the use of NAC reduces creatinine and increases GFR in patients with diabetes mellitus, which indicates that the use of NAC may prevent renal failure in these patients.
Keywords
Acetylcysteine
Cardiopulmonary bypass
Renal insufficiency
  1. Esfandiari N, Babavalian MR, Moghadam AME, Tabar VK. Knowledge discovery in medicine: Current issue and future trend. Expert Syst Appl 2014; 41(9): 4434-63.
  2. Koohi F, Salehiniya H, Mohammadian Hafshejani A. Trends in mortality from cardiovascular disease in Iran from 2006-2010. J Sabzevar Univ Med Sci 2015; 22(4): 630-8. [In Persian].
  3. Rahimi E, Moradi M, Salehi G, Nabati M. Association between socio-economic factors and geographical pattern of death due to cardiovasculardiseases in Kurdistan Province. J Mazandaran Univ Med Sci 2020; 29(182): 62-72.
  4. [In Persian].
  5. Liu D, Liu B, Liang Z, Yang Z, Ma F, Yang Y, et al. Acute kidney injury following cardiopulmonary bypass: a challenging picture. Oxid Med Cell Longev 2021; 2021: 8873581.
  6. Ortega-Loubon C, Fernandez-Molina M, Paneda-Delgado L, Jorge-Monjas P, Carrascal Y. Predictors of postoperative acute kidney injury after coronary artery bypass graft surgery. Braz J Cardiovasc Surg 2018; 33(4): 323-9.
  7. de Somer F, Mulholland JW, Bryan MR, Aloisio T, Van Nooten GJ, Ranucci M. O2 delivery and CO2 production during cardiopulmonary bypass as determinants of acute kidney injury: time for a goal-directed perfusion management? Crit Care 2011; 15(4): R192.
  8. Ghosh S, Falter F, Cook DJ. Cardiopulmonary bypass. Cambridge, UK: Cambridge University Press; 2009.
  9. Adil M, Amin SS, Mohtashim M. N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol 2018; 84(6): 652-9.
  10. Zhao Y, Zhang S, Zhang X. Progress of the antioxidant effect of N-acetylcysteine in treatment of acute respiratory distress syndrome. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020; 32(12): 1530-2. [In Chinese].
  11. Savluk OF, Guzelmeric F, Yavuz Y, Cevirme D, Gurcu E, Ogus H, et al. N-acetylcysteine versus Dopamine to Prevent Acute Kidney Injury after Cardiac Surgery in Patients with Preexisting Moderate Renal Insufficiency. Braz J Cardiovasc Surg 2017; 32(1): 8-14.
  12. Pereira JEG, El DR, Braz LG, Escudero J, Hayes J, Johnston BC. N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials. PLoS One 2019; 14(5): e0213862.
  13. Adabag AS, Ishani A, Koneswaran S, Johnson DJ, Kelly RF, Ward HB, et al. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: A randomized controlled trial. Am Heart J 2008; 155(6): 1143-9.
  14. El-Hamamsy I, Stevens LM, Carrier M, Pellerin M, Bouchard D, Demers P, et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2007; 133(1): 7-12.
  15. Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: A randomized controlled trial. JAMA 2005; 294(3): 342-50.
  16. Zhu J, Yin R, Shao H, Dong G, Luo L, Jing H. N-acetylcysteine to ameliorate acute renal injury in a rat cardiopulmonary bypass model. J Thorac Cardiovasc Surg 2007; 133(3): 696-703.

  • Receive Date 10 January 2021
  • Accept Date 06 April 2022